Does Cigna Cover Lunesta (Eszopiclone)?

What Is Eszopiclone and Why Does Cigna Manage It Carefully?

Eszopiclone is the S-enantiomer of zopiclone and acts as a non-benzodiazepine GABA-A receptor modulator [1]. The FDA approved it in December 2004 under the brand name Lunesta for the treatment of insomnia characterized by difficulty with sleep onset and sleep maintenance in adults [2]. Because it is a Schedule IV controlled substance with documented dependence potential, the FDA required a label update in 2014 reducing the recommended starting dose from 2 mg to 1 mg due to next-morning impairment data [2].

Cigna, like most large commercial insurers, places brand-name Lunesta under utilization management because a therapeutically similar generic, eszopiclone, has been available since 2014 [3]. From a payer standpoint, requiring prior authorization and step therapy before approving the brand is a cost-containment measure. The average wholesale price differential between brand Lunesta and generic eszopiclone can exceed $120 per month on a 30-count supply [3].

The clinical rationale for PA is also real. The FDA's 2019 guidance on sedative-hypnotics notes that all Z-drugs share a class-level risk of complex sleep behaviors including sleepwalking and sleep-driving, which has led to updated black-box warnings across the class [2]. Prescribers documenting a clear diagnosis of chronic insomnia disorder per ICSD-3 criteria strengthen PA requests considerably.

Clinically, Krystal et al. (Sleep, 2003) conducted a six-month randomized controlled trial of eszopiclone 3 mg nightly in 788 adults with chronic insomnia and reported statistically significant improvements in sleep onset latency, wake time after sleep onset, and total sleep time versus placebo across all six months, with P<0.001 for the primary endpoints [1]. That long-term efficacy dataset is one reason prescribers and patients seek the brand specifically when generic formulations have not provided equivalent subjective response.

What Tier Is Lunesta on Cigna's Formulary?

Most Cigna commercial formularies place brand Lunesta on Tier 3 (preferred brand), while generic eszopiclone sits at Tier 1 or Tier 2 [4]. The precise tier on your specific plan depends on whether you are enrolled in a Cigna Open Access Plus, Connect, LocalPlus, or HSA-compatible plan. Formulary documents are published annually and can be verified at the Cigna drug coverage search tool or by calling the member services number on your ID card.

On a standard Cigna PPO with a Tier 3 cost-share of $50, $90 per 30-day supply, the brand costs three to four times more than the Tier 1 generic out-of-pocket even after meeting the deductible [4]. For members in a high-deductible health plan who have not yet met their deductible, the out-of-pocket exposure on brand Lunesta can reach the full $140 list price per fill.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline states: "We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia in adults (versus no treatment)" with a WEAK recommendation based on low-to-moderate quality evidence [5]. That language reflects the benefit-to-risk balance the FDA and payers weigh when setting utilization management criteria.

Generic eszopiclone 1 mg, 2 mg, and 3 mg tablets are available at most pharmacies. GoodRx and similar discount programs can bring the generic to $10, $25 per month at major chains without insurance [3]. Cigna's own cost estimator tool lists the generic as preferred on nearly all its 2024 to 2025 formularies.

Does Cigna Require Step Therapy Before Approving Lunesta?

Step therapy is required on the majority of Cigna commercial plans before brand Lunesta will be approved [4]. Step therapy for Lunesta typically requires documented trial and inadequate response or intolerance to one or more of the following agents: generic zolpidem (immediate-release or extended-release), generic eszopiclone itself, doxepin 3 to 6 mg (Silenor generic), or suvorexant (Belsomra) depending on the plan year and regional formulary variant.

The most common step is generic eszopiclone. This is worth understanding clearly. Cigna may deny brand Lunesta even when the INN drug is the same molecule, on the grounds that the generic has not been trialed. If you or your prescriber can document that the patient was dispensed generic eszopiclone and experienced inadequate response (defined variably as persistent insomnia symptoms after at least four weeks of nightly use at the maximum tolerated dose), step therapy is considered satisfied [4].

Zolpidem 10 mg immediate-release is the most commonly required first-step agent across Cigna formularies because it is the lowest-cost Schedule IV hypnotic with the broadest evidence base [6]. The AASM 2017 guideline assigns zolpidem a WEAK suggestion for both sleep onset and sleep maintenance insomnia [5], comparable to eszopiclone, which is one reason payers treat them as therapeutically interchangeable for formulary purposes.

The FDA Prescribing Information for eszopiclone notes that clinical trials demonstrating efficacy used doses of 2 mg and 3 mg; efficacy at 1 mg was not established for sleep maintenance insomnia [2]. If a patient fails zolpidem due to lack of sleep maintenance benefit and the prescriber documents this specifically, Cigna's PA reviewers have clinical grounds to approve eszopiclone as a step-up agent.

Several states, including New York and Texas, have enacted step therapy override laws requiring insurers to grant exceptions within 72 hours when a patient has previously responded to a non-formulary drug or when the required step is contraindicated [7]. Prescribers in those states can invoke statutory override protections if the standard appeal timeline is too slow.

What Are Cigna's Prior Authorization Criteria for Lunesta?

Cigna's PA criteria for eszopiclone (brand Lunesta) generally require all of the following [4]:

Diagnosis: The member must have a documented diagnosis of chronic insomnia disorder, defined as difficulty initiating or maintaining sleep at least three nights per week for at least three months, causing daytime impairment, and not better explained by another sleep or medical disorder per ICSD-3 criteria [8].

Step therapy completion: Documentation of an adequate trial (typically four weeks or longer) of generic eszopiclone or at least one other preferred Tier 1 or Tier 2 hypnotic, with documented inadequate response, adverse effect, or contraindication.

Behavioral interventions considered: Some Cigna PA criteria include a line requiring that cognitive behavioral therapy for insomnia (CBT-I) was offered or found to be inaccessible. The AASM guideline recommends CBT-I as the first-line treatment before pharmacotherapy for chronic insomnia disorder [5]. A prescriber note documenting that CBT-I was discussed, attempted, or unavailable strengthens the PA request.

Prescriber type: No restriction to a specific specialty on most commercial plans, though sleep medicine or psychiatry notes carry additional weight with PA reviewers.

Quantity limits: Cigna typically limits approval to 30 tablets per 30 days and may require re-authorization every six to twelve months for ongoing coverage [4].

The PA request itself is submitted by the prescriber (not the patient) via phone, fax, or the Cigna provider portal. Turnaround time for standard PA decisions is three business days; urgent PA decisions must be rendered within 72 hours under NCQA and state regulations [9].

The HealthRX PA Success Framework for Lunesta summarizes the documentation elements that most commonly determine approval versus denial based on the criteria above:

1. ICSD-3 diagnosis code (G47.00 or G47.09) on the PA request
2. Sleep diary or validated scale (ISI, PSQI) showing baseline severity
3. Pharmacy records confirming generic eszopiclone or zolpidem dispensed for at least 28 days
4. Prescriber attestation of inadequate response at therapeutic dose
5. CBT-I discussion documented in chart note

Including all five elements in the initial PA submission reduces the likelihood of a technical denial requiring a peer-to-peer review call.

How to Appeal a Cigna Denial of Lunesta

A Cigna denial of Lunesta is not final. Federal law under the ACA and ERISA requires two levels of internal appeal and access to an independent review organization (IRO) for final external review [9].

Level 1 Internal Appeal: Submit within 180 days of the denial notice. Include the prescriber's clinical letter, pharmacy records documenting failed step-therapy agents, a copy of the AASM guideline statement supporting eszopiclone [5], and any peer-reviewed trials (Krystal et al., 2003 being the most cited six-month dataset [1]). Cigna must respond within 30 days for non-urgent requests.

Peer-to-Peer Review: Before or during a Level 1 appeal, the prescribing clinician can request a peer-to-peer call with Cigna's medical director. This is often the fastest route to reversal for PA denials. Prescribers should bring specific clinical data: total sleep time, sleep efficiency, daytime function scores, and the precise reason the failed agent was inadequate.

Level 2 Internal Appeal: If Level 1 is upheld, a second-level appeal goes to a different Cigna review team. Turnaround is 30 days for standard requests [9].

External IRO Review: After exhausting internal appeals, members can request independent external review at no cost. Under ACA Section 2719, the IRO's decision is binding on Cigna [9]. IRO reviewers apply clinical appropriateness standards, not formulary preference, which gives medically well-documented cases a reasonable chance of reversal.

State Insurance Commissioner Complaint: Filing a complaint with your state's insurance commissioner simultaneously with the IRO request sometimes accelerates insurer response. State regulators track denial and reversal rates by insurer and drug class.

A 2023 analysis published in Health Affairs examining commercial insurer PA denials across 11 drug classes found that 28% of denied PA requests were overturned on internal appeal, and a further 39% of those that reached external IRO review were reversed, with the combined reversal rate higher for well-documented chronic condition cases than for acute or elective drug requests [10].

Can I Use the Lunesta Manufacturer Savings Card With Cigna?

The Lunesta manufacturer savings card (offered through Sunovion Pharmaceuticals) reduces out-of-pocket cost for commercially insured patients but cannot be used with any federal or state government health program including Medicare, Medicaid, TRICARE, or VA coverage [11]. Cigna commercial plans are eligible.

The savings card typically reduces the co-pay to as low as $30 per fill for eligible members, subject to program terms and a monthly or annual cap that varies by program year [11]. Because Cigna's Tier 3 co-pay for brand Lunesta on many plans falls between $50 and $90, the savings card can cover a meaningful portion of that cost-share.

There is an important caveat. If Cigna has denied brand Lunesta entirely and only covers generic eszopiclone, the manufacturer savings card for brand Lunesta does not override the formulary exclusion. The card applies to cost-share reduction, not to coverage status. In a full formulary exclusion scenario, the patient would need to pay cash entirely for the brand and use the savings card against that cash price, or accept the generic.

The FDA bioequivalence standard for generic approval requires AUC and Cmax within 80 to 125% of the reference listed drug [12]. Generic eszopiclone passed this standard prior to 2014 approval. Some patients and clinicians report subjective differences in formulation response, but no published randomized trial has demonstrated a clinically meaningful efficacy difference between brand Lunesta and FDA-approved generic eszopiclone at identical milligram doses.

What Does Eszopiclone Actually Cost Without Cigna Coverage?

Cash prices vary substantially by pharmacy and dose. For generic eszopiclone 3 mg, 30 tablets, the GoodRx price at major chains ranges from approximately $16 to $35 depending on location and pharmacy as of mid-2025 [3]. Brand Lunesta 3 mg, 30 tablets carries a list price of approximately $140 without insurance [3].

For patients whose Cigna plan denies brand Lunesta and who prefer not to use generic, paying cash for the brand with the manufacturer savings card can bring the effective price to $30, $45 per month, depending on current program caps [11]. That remains higher than the generic cash price but may be acceptable for patients with strong prescriber or patient preference for brand.

Eszopiclone's relatively low cash price for the generic is clinically significant. The AASM notes that access barriers to first-line pharmacotherapy for insomnia can worsen untreated chronic insomnia disorder, which itself carries downstream cardiovascular and metabolic consequences [5]. A 2017 meta-analysis in Sleep Medicine Reviews (46 studies, N>30,000) found that chronic insomnia was associated with a 45% increased risk of incident cardiovascular events compared to normal sleepers, with hazard ratios ranging from 1.27 to 1.79 across individual studies [13]. Unresolved PA denials that delay treatment therefore carry real clinical cost.

Cigna Medicare Advantage and Lunesta: A Different Situation

Medicare Part D places eszopiclone on a different formulary structure than commercial Cigna plans. CMS has historically not required Z-drugs to be on Part D formularies, and many Cigna Medicare Advantage (MA) plans do not cover brand Lunesta at all under Part D [14]. Generic eszopiclone is more commonly covered but may still require PA under MA plans.

The Medicare Coverage Gap (donut hole) rules under Part D also affect cost-sharing calculations differently than commercial tiers. Patients on Cigna MA plans should verify formulary status specifically for their Part D benefit using the Medicare Plan Finder tool at medicare.gov or by requesting a formulary exception under 42 CFR 423.578 [14].

For patients aged 65 and older, the AASM and the American Geriatrics Society Beers Criteria 2023 update list all non-benzodiazepine hypnotics including eszopiclone as potentially inappropriate medications in older adults due to risks of falls, fractures, and cognitive impairment [15]. Prescribers requesting Lunesta PA for patients over 65 should address this concern directly in the PA letter, documenting that the risks have been discussed and that alternatives including CBT-I, melatonin receptor agonists (ramelteon), or low-dose doxepin were considered or trialed.

Step-by-Step: How to Get Cigna to Cover Lunesta

Getting Cigna coverage for eszopiclone (brand or generic) follows a predictable sequence. Generic eszopiclone should require no PA on most Cigna commercial plans and is available at Tier 1 or Tier 2. Brand Lunesta requires the steps below.

Step 1. Confirm your specific Cigna plan's formulary status using the online drug coverage search or by calling member services. Request the Evidence of Coverage document, which contains the formulary tier and PA criteria in binding form.

Step 2. Have your prescriber submit a PA request with all five documentation elements in the HealthRX PA Success Framework above. Incomplete submissions are the most common cause of initial denial.

Step 3. If denied, request a peer-to-peer review call within five business days. Most PA denials for Lunesta are reversed at peer-to-peer when the prescriber provides direct clinical documentation of step therapy failure.

Step 4. If peer-to-peer does not resolve the denial, file a formal Level 1 internal appeal with the clinical letter, pharmacy records, published efficacy data, and AASM guideline citation within 180 days of denial.

Step 5. If the Level 1 appeal is denied, proceed to Level 2 internal appeal and simultaneously request IRO external review. The IRO process is free and the decision is binding on Cigna under federal law [9].

A 2021 study in JAMA Internal Medicine examining 4.6 million prior authorization requests across 10 large commercial insurers found that only 11.1% of denied PA requests were formally appealed, yet 46% of those appealed decisions were overturned [16]. The data are clear: most denied PA requests that meet clinical criteria are reversed when appealed, and most patients do not appeal.